Heineman Thomas Charles 4

What Happened Thomas Charles Heineman, Chief Medical Officer of Oncolytics Biotech Inc. (ONCY), made an open-market purchase of 12,132 shares of ONCY common stock on February 12, 2026. The shares were acquired at $0.83 per share for a total reported value of approximately $10,033. This was a purchase (code P), which is generally considered a more informative signal than routine sales, though the amount is modest.

Key Details

• Transaction date: 2026-02-12 (reported on Form 4 filed 2026-02-13)
• Transaction type: Open-market purchase (Code P)
• Price per share: $0.83
• Shares acquired: 12,132
• Total value: ~$10,033
• Shares owned after transaction: Not specified in the provided filing summary
• Footnotes/plan: No 10b5-1 plan, tax withholding, or other special footnotes reported in the provided details
• Filing timeliness: Reported promptly (Form 4 filed the next day); not indicated as late

Context This was a straightforward buy of common stock by an executive (CMO), not a reported gift or option exercise. The purchase size is relatively small, so while it shows insider buying interest, it should be weighed alongside other insider transactions and company fundamentals before drawing conclusions.